Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS

NCT04881045 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04881045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04881045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2021
Completion date
October 24, 2023
Enrollment
29 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck